LB Pharmaceuticals Inc entered into a Securities Purchase Agreement on July 28, 2026, to raise approximately $150 million in gross proceeds through a private placement. The company sold 3,577,560 shares of common stock at $34.94 per share and pre-funded warrants for up to 715,513 additional shares at $34.9399 each. Proceeds are intended to fund pipeline expansion for its lead candidate LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, as well as working capital. The transaction closed on July 30, 2026, with Leerink Partners LLC and Piper Sandler & Co. acting as placement agents. LB Pharmaceuticals is a neuromedicines company developing therapies for underserved brain diseases.
